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Objectives: Extracorporeal membrane oxygenation provides short-
term cardiopulmonary life support, but is associated with periph-
eral innate inflammation, disruptions in cerebral autoregulation, 
and acquired brain injury. We tested the hypothesis that extra-
corporeal membrane oxygenation also induces CNS-directed 
adaptive immune responses which may exacerbate extracorporeal 
membrane oxygenation-associated brain injury.
Design: A single center prospective observational study.
Setting: Pediatric and cardiac ICUs at a single tertiary care, aca-
demic center.
Patients: Twenty pediatric extracorporeal membrane oxygenation 
patients (0–14 yr; 13 females, 7 males) and five nonextracorpo-
real membrane oxygenation Pediatric Logistic Organ Dysfunction 
score matched patients
Interventions: None.
Measurements and Main Results: Venous blood samples were 
collected from the extracorporeal membrane oxygenation circuit 
at day 1 (10–23 hr), day 3, and day 7 of extracorporeal mem-
brane oxygenation. Flow cytometry quantified circulating innate 
and adaptive immune cells, and CNS-directed autoreactivity was 
detected using an in vitro recall response assay. Disruption of ce-
rebral autoregulation was determined using continuous bedside 
near-infrared spectroscopy and acquired brain injury confirmed 
by MRI. Extracorporeal membrane oxygenation patients with ac-
quired brain injury (n = 9) presented with a 10-fold increase in 
interleukin-8 over extracorporeal membrane oxygenation patients 
without brain injury (p < 0.01). Furthermore, brain injury within 
extracorporeal membrane oxygenation patients potentiated an 
inflammatory phenotype in adaptive immune cells and selective 
autoreactivity to brain peptides in circulating B cell and cytotoxic 
T cell populations. Correlation analysis revealed a significant re-
lationship between adaptive immune responses of extracorporeal 
membrane oxygenation patients with acquired brain injury and 
loss of cerebral autoregulation.
Conclusions: We show that pediatric extracorporeal membrane 
oxygenation patients with acquired brain injury exhibit an induction 
of pro-inflammatory cell signaling, a robust activation of adaptive 
immune cells, and CNS-targeting adaptive immune responses. As 
these patients experience developmental delays for years after ex-DOI: 10.1097/CCM.0000000000003621
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tracorporeal membrane oxygenation, it is critical to identify and 
characterize adaptive immune cell mechanisms that target the de-
veloping CNS. (Crit Care Med 2019; 47:e206–e213)
Key Words: autoreactivity; B cells; cerebral autoregulation; 
cytotoxic T cells; extracorporeal membrane oxygenation; helper T 
cells
Extracorporeal membrane oxygenation (ECMO) is a com-plex technique that provides life support during severe respiratory and/or cardiac failure (1). The expanded use 
of ECMO in pediatric patients reveals a number of complica-
tions, including an acute induction of systemic inflammatory 
response syndrome (SIRS), long-term neurodevelopmental 
deficits, and an increasing number of children exhibiting neu-
rologic morbidities (1, 2). In fact, acquired neurologic injury is 
a significant risk factor, secondary to detrimental mechanisms 
associated with the underlying disease that contributes to both 
morbidity and mortality in patients on ECMO (3).
ECMO circuits expose blood to artificial surfaces and ac-
tivate the coagulation and complement systems (4). This can 
induce a robust innate (i.e., primary) immune response, that 
is, similar to SIRS (5). Additionally, ECMO increases the pro-
duction of interleukin (IL)–1β, IL-6, IL-8, IL-10, and tumor ne-
crosis factor-α within hours of initiation (5). Complement and 
pro-inflammatory cytokines activate neutrophils and promote 
migration into target organs (e.g., lungs) which further exacer-
bate pathology (6, 7). Similarly, monocytes are also activated by 
ECMO, although their activation rate is much slower (8). The 
contribution of adaptive immunity during ECMO neuropa-
thology, however, remains unstudied despite the contribution 
of adaptive immune mechanisms to similar inflammatory neu-
rologic diseases (9). ECMO promotes cytokine production and 
precipitates disruptions in cerebral blood flow (CBF) which fa-
cilitate CNS antigen release into the periphery—both necessary 
steps to CNS-directed adaptive immunity. Thus, the primary 
objective of this pilot study is to test the hypothesis that ECMO 
initiates CNS-targeting adaptive immunity that may contribute 
to long-term ECMO-induced neurologic injury.
MATERIALS AND METHODS
Human Subjects
This is a prospective pilot observational study in patients (0–18 
yr old) who underwent venoarterial and venovenous ECMO in 
pediatric and cardiac ICUs at Children’s Health (Supplemental 
Table 1, Supplemental Digital Content 1, http://links.lww.
com/CCM/E238; exclusions are shown in Fig. 1). The study 
was approved by the University of Texas Southwestern Med-
ical Center Institutional Review Board. Healthy control plasma 
samples were obtained from volunteers (STU122013-036). Sick 
control patients who were Pediatric Logistic Organ Dysfunc-
tion (PELOD) score matched were also enrolled (Supplemental 
Table 2, Supplemental Digital Content 1, http://links.lww.com/
CCM/E238). Demographic, clinical, laboratory, imaging, and 
outcome data were obtained from the medical chart for each 
subject. Routine brain MRI was done for most patients after 
ECMO. Brain injury was defined as abnormal brain MRI find-
ings with or without clinical correlation, as determined by 
a licensed neuroradiologist, with images as standard of care 
and not specifically collected for this project. All patients were 
placed on Rotaflow centrifugal pumps, cannulation for venoar-
terial was through carotid artery and internal jugular vein and 
for venovenous through double lumen cannulas placed in the 
right internal jugular vein. Heparin was the anticoagulation of 
choice. All patients were sedated with fentanyl and versed, and 
dexmedetomidine was used as an adjunct in some patients.
Study Design
At the bedside, cerebral autoregulation measurements were 
collected over the course of ECMO. Bedside blood draws were 
collected on day 1 (within 10–23 hr of cannulation), day 3, and 
day 7 of ECMO. Blood was processed for an immediate leuko-
cyte survey by flow cytometry (gating shown in Supplemental 
Fig. 2, Supplemental Digital Content 1, http://links.lww.com/
CCM/E238). Plasma and immune cells were additionally 
banked for enzyme-linked immunosorbent assay (ELISA) and 
autoimmune assay, with all time points of each patient assayed 
concurrently.
For detailed methodologies pertaining to peripheral blood 
mononuclear cells flow cytometry, carboxyfluoresceine suc-
cinimidyl ester proliferation assay, ELISA, adaptive immune 
modulation, cerebral autoregulation, and neuroimaging 
methods (see Supplemental Digital Content 1, http://links.
lww.com/CCM/E238).
Statistics
The data obtained were assumed to be nonparametric and ana-
lyzed using GraphPad Prism software (San Diego, CA). Kruskal-
Wallis with uncorrected Dunn multiple comparisons test, two-way 
analysis of variance with Fisher Least Significant Difference mul-
tiple comparison, Kolmogorov-Smirnov rank-sum test for organ 
dysfunction, and Mann-Whitney U tests were used to compare 
data by day and between cohorts. All tests were two-tailed, and 
significance was set as p value of less than 0.05. Values presented in 
text are mean ± sd. Spearman correlation analysis was used to cor-
relate autoregulation and neuroimaging scores with absolute cell 
counts and cytokines. This study was not adequately powered for 
venoarterial ECMO subgroup analyses alone. One patient on day 
1 and another on day 3 were identified as outliers and excluded 
from the atypical lymphocyte differential analysis.
RESULTS
ECMO Patient Cohort
Within the ECMO patient cohort, three patients had a clin-
ical change in neurologic examination, and an additional five 
patients had neurologic injury identified by standard-of-care 
post-ECMO MRI (Fig. 1; and Supplemental Table 1, Supple-
mental Digital Content 1, http://links.lww.com/CCM/E238). 
An additional patient presented with infarcts prior to placement 
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on ECMO. Together, these patients were identified as “acquired 
brain injury” patients. Three patients with white matter injury 
related to prematurity, and an additional eight patients without 
neurologic deficits and/or neuroimaging abnormalities, were 
identified as “no brain injury.” There was no difference in the par-
tial thromboplastin time goals or heparin infusion in U/kg/d be-
tween patients with and without brain injury (Supplemental Fig. 
1, Supplemental Digital Content 1, http://links.lww.com/CCM/
E238), although patients with brain injury presented with lower 
anti-Xa levels and received more platelets (Supplemental Fig. 1, 
C and D, Supplemental Digital Content 1, http://links.lww.com/
CCM/E238). There was also no difference in severity of organ dys-
function (kidney and liver) between ECMO cohorts (blood urea 
nitrogen, creatine, aspartate amino transferase, alanine amino 
transferase, and alkaline phosphatase). For all ECMO patients (n 
= 20), we observed acute increases in plasma IL-6 and IL-8 (p 
< 0.01) compared with disease-only patients (n = 5) (Fig. 2, A 
and B), in accordance with previous results (5). Grouped analyses 
using flow cytometry (Supplemental Fig. 2, Supplemental Digital 
Content 1, http://links.lww.com/CCM/E238) revealed a trend to-
ward an increase of peripheral CD4 T cell cellularity on day 3 
of ECMO (p = 0.06) (Supplemental Fig. 3, Supplemental Dig-
ital Content 1, http://links.lww.com/CCM/E238) compared with 
sick controls, as the only adaptive immune response. Concomi-
tant analyses of innate cellularity revealed minimal elevation of 
innate cell subsets in grouped ECMO-treated patients versus sick 
control patients. Finally, we analyzed differential counts taken as 
standard-of-care diagnostics, including pre-ECMO counts not 
available for the flow cytometry analysis (Supplemental Fig. 4, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
E238). For neutrophil, lymphocyte, atypical lymphocyte, and 
monocyte counts, only monocytes were elevated on day 3 com-
pared with all other days (Supplemental Fig. 4D, Supplemental 
Digital Content 1, http://links.lww.com/CCM/E238).
Figure 1. Enrollment diagram. This diagram shows all enrollment for 
this pilot study, including status/post (s/p) exclusion criteria. Patient 
recruitment was determined a prior to be completed after 20 patients. 
CPR = cardiopulmonary resuscitation, ECMO = extracorporeal membrane 
oxygenation, PI = principal investigator, VA = venoarterial, VV = venovenous.
Figure 2. Cytokine levels are elevated in extracorporeal membrane oxygenation (ECMO) patients with acquired brain injury. ECMO induces early 
cytokine up-regulation for (A) interleukin (IL)–6 and (B) IL-8 at day 1 of ECMO (n = 20) compared with disease-control patients without ECMO (n = 5). 
Circle shapes are nonbrain injury patients, and triangles represent brain injury patients. C, Heat map representation of all mean ± sd values (text shown, 
pg/mL) of cytokines separated by brain injury status. Significance is defined as *p < 0.05, **p < 0.01 by nonparametric Kruskal-Wallis analysis of variance 
versus sick control shown in the far left column of the heat map.
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Plasma From ECMO/Brain-Injured Patients Drives 
Healthy Adaptive Immune Cells Toward a Pro-
Inflammatory Phenotype
When segregating patients according to the presence of brain 
injury (Fig. 2C), the brain injury group exhibited greater eleva-
tions in pro-inflammatory IL-6 on day 1 of ECMO (p < 0.01 
vs sick control). The greatest response, however, came from 
the neutrophil chemotactic factor IL-8, which increased over 
10-fold in brain-injured ECMO patients (p < 0.01 vs sick con-
trol) and continued to be elevated on day 3 (p < 0.05 vs sick 
control) and day 7 of ECMO. IL-8 promotes adaptive T helper 
(Th) cell recruitment and activation of neutrophils, which fur-
ther drives the induction of pro-inflammatory Th1 and Th17 
cells (10). We used peripheral plasma to indirectly ascertain in-
duction of inflammatory adaptive immune cells and found that 
plasma from ECMO brain-injured patients activated helper 
(p < 0.001) and cytotoxic (p < 0.01) T cells and B cells (p < 0.01) 
(Fig. 3; and Supplemental Fig. 5, Supplemental Digital Con-
tent 1, http://links.lww.com/CCM/E238) compared with acti-
vation by plasma collected from ECMO patients without brain 
injury or sick patient controls. Brain-injured ECMO-derived 
plasma also drove increased production of IL-17 in helper T 
cells (p < 0.0001) and B cells (p < 0.001), with a concomitant 
loss in IL-17-producing cytotoxic T cells in brain injury co-
cultures relative to nonbrain injury (p = 0.05), an interesting 
phenomenon that requires fur-
ther investigation. Only B cells 
increased interferon (IFN)–γ 
production with brain-injured 
plasma (p < 0.001) (Supple-
mental Fig. 5D, Supplemental 
Digital Content 1, http://links.
lww.com/CCM/E238). These 
data suggest that patients on 
ECMO and experiencing brain 
injury possess an environment 
within their circulation that is 
conducive to initiating an acti-
vated, pro-inflammatory adap-
tive immune response.
Noncanonical 
Inflammatory Immune 
Cells Are Elevated in 
ECMO/Brain Injury 
Patients
Surprisingly, during our leu-
kocyte survey, we came across 
adaptive immune cells that did 
not express cardinal adaptive 
immune cell markers. Rarely 
described, T cells expressing 
CD161+ produce IL-17 and 
are postulated to contribute 
to immune-mediated neuro-
logic diseases (11). Grouped 
ECMO patients exhibited a decrease in cellularity of activated 
(i.e., CD161+) helper T cells at day 1 (p < 0.05) and day 3 
(p < 0.05) of ECMO (Supplemental Fig. 6, Supplemental Dig-
ital Content 1, http://links.lww.com/CCM/E238) compared 
with sick controls. These populations were, however, elevated 
in ECMO patients with brain injury, including activated B cells 
(day 1; p < 0.05), natural killer T cells (day 3; p < 0.05 and day 
7; p < 0.001) and cytotoxic T cells (day 7; p < 0.05) compared 
with ECMO patients without brain injury (Supplemental 
Fig. 7, Supplemental Digital Content 1, http://links.lww.com/
CCM/E238). These patients with brain injury had concomi-
tant elevations in activated macrophages (Supplementary Fig. 
7F, Supplemental Digital Content 1, http://links.lww.com/
CCM/E238) across the full course of ECMO. This shows that 
in patients presenting with acquired brain injury there is an 
increase in highly inflammatory circulating adaptive immune 
populations not identified in standard-of-care immune cell 
differential counts (Supplemental Fig. 4 E–H, Supplemental 
Digital Content 1, http://links.lww.com/CCM/E238).
ECMO/Brain Injury Coincides With Increased CNS-
Specific Autoreactive Cytotoxic T Cells
CNS antigen presentation to, and subsequent activation of, 
adaptive immune cells can lead to the induction of CNS-
targeting adaptive immune responses (12–15), with these 
Figure 3. Plasma from brain-injured patients supported with extracorporeal membrane oxygenation 
(ECMO) drives healthy adaptive immune cells toward a pro-inflammatory phenotype. Black bar graphs show 
nonparametric Kruskal-Wallis analysis of variance results for triplicate experiments for activation status (CD25+, 
n = 6) of (A) CD4+ helper T cells, (B) CD8+ cytotoxic T cells, and (C) CD19+ B cells after exposure to healthy 
plasma-containing media (left columns, squares, n = 5), or ECMO patient-derived plasma-containing media 
from patients without brain injury (middle columns, circles, n = 2), or with brain injury (right columns, triangles, 
n = 4). Permutations of test conditions resulted in 10 test conditions for control plasma, six for nonbrain injury 
ECMO, and 13 for brain injury ECMO. Plasma from ECMO patients with brain injury also elevated intracellular 
interleukin (IL)–17 production in (D) helper T cells and (F) B cells, but not (E) cytotoxic T cells. Values are mean 
± sd and significance between groups on an individual day is shown as *p < 0.05, **p < 0.01, ***p < 0.001, ****p 
< 0.0001 versus healthy plasma unless otherwise indicated by brackets.
Ortega et al
e210 www.ccmjournal.org March 2019 • Volume 47 • Number 3
autoreactive adaptive immune responses sufficiently capable 
of inducing brain injury, as seen in other CNS diseases (15, 16). 
Thus, we determined if ECMO-treated patients exhibited 
adaptive immune cell responses that target CNS-specific pep-
tides, including myelin and neuronal peptides (Supplemental 
Table 3, Supplemental Digital Content 1, http://links.lww.
com/CCM/E238) (12, 13, 15). All responses were compared 
with an unstimulated sample response to control for the un-
derlying generalized inflammatory disease state unique to each 
patient (Supplemental Table 1, Supplemental Digital Content 
1, http://links.lww.com/CCM/E238). We used banked samples 
from sick PELOD-matched control patients (n = 4), ECMO 
patients without brain injury (n = 9), and ECMO patients that 
presented with acquired brain injury (n = 7).
CNS-targeted autoreactivity in helper T cells was similar in 
magnitude between all cohorts (Fig. 4; and Supplemental Fig. 8, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
E238), although fewer patients with brain injury had autoreactive 
cells (three out of seven patients, day 1 of ECMO) compared with 
the non brain-injured ECMO cohort (eight out of eight patients) 
(Fig. 4A). The magnitude of helper T cell autoreactivity signifi-
cantly diminished in the brain-injured cohort over the course of 
ECMO (day 1 vs day 7; p < 0.05), although day 7 is limited in patient 
sample size, with only two patients in the acquired brain injury 
cohort. In contrast, the magnitude of autoreactivity for cytotoxic 
T cells in ECMO patients peaked at day 3 (p < 0.05 vs days 1 and 
7) (Supplemental Fig. 7D, Supplemental Digital Content 1, http://
links.lww.com/CCM/E238), with a consistently higher magnitude 
of autoreactivity in the brain-injured ECMO patients on both day 1 
(p < 0.01) and day 3 (p < 0.05) of ECMO (Fig. 4B). Autoimmune 
responses for cytotoxic T cells were not detectable at day 7 
of ECMO. The cytotoxic T cell responses to both myelin and 
neuronal peptides were driven by a smaller subset of patients 
(~25–40% of patients), which was different from the helper T cell 
response that often included autoreactivity in 60–100% of the 
patients tested.
B cell autoreactivity was also much higher in the ECMO-
treated patients over sick control patients (Supplemental Fig. 
8F, Supplemental Digital Content 1, http://links.lww.com/
CCM/E238). When analyzed based on brain injury status, 
B cell autoreactivity to CNS antigens is unique on day 1 of 
ECMO, as it is significantly elevated in the ECMO patients 
without brain injury (p < 0.01) (Fig. 4C). For the ECMO 
patients without brain injury, this early and high level of CNS-
directed autoreactivity significantly diminished at both day 3 
(p < 0.001 vs day 1) and day 7 (p < 0.01 vs day 1) of ECMO. In 
contrast, ECMO patients with brain injury exhibited a delayed 
increase in autoreactivity on day 3 (p < 0.05). Although half 
of the ECMO patients (4/8) 
without brain injury exhibited 
autoreactivity to myelin and 
neuronal peptides on day 1, the 
day 3 response in the brain in-
jury cohort overall was driven 
by the response in two patients. 
In summary, ECMO treatment 
coincided with autoreactivity 
to CNS-specific antigens in cy-
totoxic T cell and B cells.
Disrupted Cerebral 
Autoregulation Correlates 
With Adaptive Immune 
Responses for ECMO 
Patients With Brain Injury
Pediatric patients on ECMO 
exhibit disturbances in cerebral 
autoregulation (17), which is 
the brain’s ability to maintain 
constant CBF despite changes 
in systemic blood pressure (18). 
Continuous near-infrared spec-
troscopy bedside monitoring 
can identify disrupted cerebral 
autoregulation for several dis-
eases associated with secondary 
neurologic injury, including 
ECMO (17, 19, 20). In our pa-
tient population, 13 patients 
were simultaneously enrolled in 
Figure 4. Brain injury associated with cytotoxic T cell autoreactivity to CNS antigens. Autoreactivity data 
separated by brain injury were analyzed by two-way analysis of variance, Fisher Least Significant Difference. 
Positive responses (change in proliferation fraction [ΔPF]) from all patients tested (#/#) and corresponding 
% indicated below graph. A, CD4 helper T cell responses did not differ between extracorporeal membrane 
oxygenation (ECMO) patients without brain injury (circles) and those with brain injury (triangles). B, 
Autoreactive CD8 T cell responses were, however, more abundant in brain injury ECMO patients, and (C) B cell 
autoreactivity was increased ECMO patients without brain injury at day 1, which was reversed by day 3 as brain-
injured ECMO patients exhibited increased autoreactivity. Significance between groups on an individual day is 
shown as *p < 0.05, **p < 0.01, ***p < 0.001 or between groups, as indicated by brackets.
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an observational study to monitor cerebral autoregulation over 
the course of ECMO, including six ECMO patients without brain 
injury, and seven with acquired brain injury. Taking the value for 
disrupted cerebral autoregulation for the duration of ECMO, we 
determined correlations between disrupted cerebral autoregula-
tion and circulating immune cells (Supplemental Table 4, Sup-
plemental Digital Content 1, http://links.lww.com/CCM/E238). 
Only the percentage of activated helper T cells consistently cor-
related with disrupted cerebral autoregulation over the course of 
ECMO. Once data were parsed between ECMO patients with and 
without brain injury (Table 1), the majority of significant corre-
lations between adaptive immune cell subsets and disruptions in 
cerebral autoregulation were driven by the brain-injured ECMO 
patients. This shows that patients who exhibit disruptions in ce-
rebral autoregulation experience concomitant activation of the 
adaptive immune system.
DISCUSSION
ECMO is a complex technique used in cases where trauma, 
sepsis, congenital heart disease, or respiratory failure necessi-
tates cardiopulmonary support. There has been a steady increase 
in pediatric ECMO usage (21, 22), but secondary complications 
increase morbidity and mortality and include ischemic stroke, 
intracranial hemorrhage, and seizures (23–25). For the first 
time, we show in this pilot study that pediatric ECMO results 
in the loss of cerebral autoregulation concomitant with a ro-
bust mobilization and activation of adaptive immune cells, 
detection of CNS-targeting adaptive immune responses, and 
induction of pro-inflammatory cell signaling predominantly in 
patients that present with acquired brain injury. We previously 
reported that acquired brain injuries could be predicted by loss 
of cerebral autoregulation in pediatric ECMO patients (17). 
What is critical to consider is that as cerebral autoregulation 
is disrupted, the blood flow in the brain is no longer constant 
but fluctuates similar to the systemic circulation. Subsequent 
higher shear stress at the capillaries could disrupt the blood-
brain barrier, whereas lower shear stress within the venules 
could increase the ability of circulating leukocytes to diapedese 
into the parenchyma (26, 27). This is particularly relevant for 
patients with high levels of circulating IL-8, which induces the 
firm adherence of immune cells to the endothelial vessel walls 
(28). Increased leukocyte diapedesis under the low-flow would 
bring inflammatory (Fig. 2), activated (Fig. 3), and autoreac-
tive (Fig. 4) adaptive immune cells into contact with the brain 
parenchyma, a necessary step to further promote brain injury.
We observed a distinct cytotoxic T cell response in ECMO 
patients with brain injury at days 1 and 3 of ECMO, with CNS 
autoreactivity to myelin and neuronal peptides. These data 
TABLE 1. Correlation of Adaptive Immune Responses to Disruption of Cerebral 
Autoregulation While on Extracorporeal Membrane Oxygenation
Leukocyte Population
ECMO Patients—No Injury  
% (R2)
ECMO Patients—Brain Injury  
% (R2)
Day 1 Day 3 Day 7 Day 1 Day 3 Day 7
General leukocytes (–) 0.31 (–) 0.03 (–) 0.18 0.70a 0.71a 0.86
T cells (–) 0.06 0.12 0.20 (–) 0.43 (–) 0.24 (–) 0.22
B cells (–) 0.48 (–) 0.03 (–) 0.002 (–) 0.01 0.01 (–) 0.31
Activated B cells 0.03 0.45 0.34 (–) 0.16 0.55c (–) 0.03
Helper T cells 0.10 0.17 0.009 (–) 0.58a (–) 0.56 (–) 0.96
Activated helper T cells (–) 0.43 (–) 0.30 (–) 0.56 0.75a 0.77b 0.99c
Cytotoxic T cells 0.009 (–) 0.12 0.002 0.58a 0.54c 0.88
Activated cytotoxic T cells (–) 0.04 (–) 0.02 0.09 0.002 0.26 0.99a
Natural killer T cells 0.55 (–) 0.008 0.19 0.43 0.26 0.70
Monocytes 0.04 (–) 0.04 (–) 0.53 (–) 0.16 (–) 0.10 0.65
Activated macrophages 0.0002 (–) 0.03 (–) 0.16 0.09 0.30 0.20
Dendritic cells 0.14 0.01 (–) 0.35 (–) 0.06 (–) 0.07 (–) 0.83
Natural killer cells (–) 0.01 (–) 0.02 (–) 0.007 (–) 0.19 (–) 0.15 (–) 0.37
Granulocytes (–) 0.98b 0.35 0.93 (–) 0.24 (–) 0.21 (–) 0.99c
Patient number (n = 5) (n = 6) (n = 3) (n = 7) (n = 7) (n = 3)
ECMO = extracorporeal membrane oxygenation, R2= R square goodness of fit, linear regression, % = percent immune population, (–) = negative slope in 
correlation.
a p < 0.05.
b p < 0.01.
c p < 0.06.
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are highly suggestive that cytotoxic T cells are being mobi-
lized by the brain injury and not by the underlying disease, 
and increased T cell egress may be reflected in lower circulating 
T cell populations. In fact, the CNS targeting by these cells is 
reminiscent of similar cells found in Rasmussen’s Encephalitis, 
multiple sclerosis (MS), and the murine model of MS, which 
have all implicated inflammatory CNS-specific cytotoxic T 
cells as mediators of neuropathology (29). This is understand-
able, as the inflammatory nature of these cells would allow CNS 
access, whereas their antigen-specificity would allow them to 
target CNS resident cells (30). More in-depth experiments are 
required to ascertain the role of ECMO-induced autoreactive 
cytotoxic T cells, whose pathology may not ultimately be lim-
ited to the duration of ECMO or the underlying disease, but 
could affect neurodevelopment with long-lasting detrimental 
outcomes (3).
Surprisingly, we also detected a high number of CNS-
specific B cells in the nonbrain injured group on day 1 of 
ECMO. This phenomenon declined by day 3, just as autore-
active responses of B cells in brain-injured patients increased. 
Autoreactivity by B cells contributes to several neurologic 
diseases (14, 31, 32), with development of autoreactive CNS-
specific B cells considered extremely dangerous, as these 
cells are capable of 1) producing antibodies which target 
CNS resident cells (33) and 2) generating de novo secondary 
lymphoid tissue within the CNS (34). Thus, it was very sur-
prising those ECMO patients without brain injury exhibited 
a robust CNS-directed B cell autoreactivity. Although highly 
speculative, it is possible that some self-reactive adaptive 
immune cells play a neuroprotective or neuroreparative role 
after brain injury. In fact, peripheral antigen presentation of 
neuronal antigens in stroke patients correlates to improved 
long-term recovery (35). Thus, we are mindful of the poten-
tial for CNS autoreactivity-mediated neuroprotection and 
will dissect the role for each of these autoreactive cells in 
future studies.
Before this study, there have been several drugs which target 
inflammation, including glucocorticoids, and other immune-
modulatory agents, with the goal of altering the inflamma-
tory response preoperatively to prevent brain injury. Although 
these drugs have been successfully used in preclinical studies, 
clinical trials identified certain inadequacies of global immune 
suppression in providing neuroprotection (36, 37). In pediatric 
patients, altered CBF and induction of systemic inflammation 
may be key mechanisms of brain injury, whereas inflammatory 
mediators stemming from the adaptive system, either cellular 
(T and B cells) or cytokines (IL-8, IL-6, IFN-γ, IL-17) can be 
neurotoxic to the developing brain. Now, with the findings of 
this study, we believe that a focused suppression of the adap-
tive immune system using pharmacologic agents approved in 
other CNS diseases may have a potential neuroprotective role 
for ECMO patients at risk of acquired brain injury (38).
This study had several limitations, including small pa-
tient enrollment and cerebral autoregulation measurements 
that spanned the course of ECMO and not the specific times 
of blood draw. We also recognize that the PELOD-matched 
control patients were not as sick as patients placed on ECMO. 
Future studies should determine the long-term effects of sys-
temic inflammation, including cytokine production, loss of 
autoregulation, persistent CNS-directed autoreactivity, and 
their cumulative associations with neurocognitive and other 
developmental delays in this patient population. In addition, 
in order to elucidate the mechanisms involved in the ECMO-
induced neuro-immunological interactions, it must be deter-
mined if ECMO-activated adaptive immune cells can directly 
target CNS resident cells.
CONCLUSIONS
This small observational study highlights a previously unchar-
acterized association between disruptions in cerebral auto-
regulation, either preceding or concomitant to neuroimmune 
responses that may contribute to brain injury for pediatric 
ECMO patients. As these patients experience developmental 
delays for years after ECMO, it is critical to identify the role 
of neuroinflammatory adaptive immune cell mechanisms that 
target the developing CNS.
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